{"entity":{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","aka":["US Oncology Research"],"tldr":"McKesson runs the largest US community oncology network (about 3,000 providers) and distributes drugs, and co-owns the Sarah Cannon Research Institute.","summary":"McKesson, based in Irving, Texas, and listed as MCK, runs The US Oncology Network, the largest US community oncology network with about three thousand providers, distributes cancer drugs, and co-owns the Sarah Cannon Research Institute. Its offerings span practice management, the Value Pathways treatment pathways, the Ontada data business and research through SCRI, with McKesson Ventures also linked. OnCo connects it to community oncology and site networks and to oncology EHR and real-world data platforms. Whether a drug distributor that also owns treatment pathways and practices can keep those pathways independent is the fair question. Sarah Cannon has its own page.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.usoncology.com"}],"tags":["supporting"],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["community-oncology-networks","oncology-real-world-data"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04782687","nct03379428","nct00248287"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Irving, TX","country":"US","companyType":"cro-services","website":"https://www.usoncology.com","ticker":"MCK","investors":[],"funding":[]},"route":"/companies/mckesson-us-oncology/","neighbours":{"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/"},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/"}],"trial":[{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/"},{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/"},{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","route":"/trials/nct04782687/"},{"id":"nct03379428","kind":"trial","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","route":"/trials/nct03379428/"}],"company":[{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/"}]}}